Progyny (PGNY) Q2 2026 Earnings Call Transcript
Progyny (PGNY) reported Q2 2026 revenue of $350.5 million, up 5.3% reported (11% excluding a transition agreement), and net income of $28.1 million ($0.34/diluted share). Adjusted EBITDA rose to $62.1 million, with gross margin expanding to 25.5%. Fertility benefit revenue was $230.2 million. Full-year 2026 guidance: revenue $1.36B to $1.385B, adjusted EBITDA $233M to $240M.
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on updated guidance ranges (Q3 revenue, full-year revenue, and adjusted EBITDA) and the stated driver of sequential weakness (seasonality). Buyback pace and margin expansion provide additional support, while retention and renewal timing remain key watch items.
Market read
Record Q2 performance with expanded gross margin and updated guidance ranges, plus a clear seasonal driver for Q3, sets a concrete near-term trading narrative.
What to watch
Brownfield switching and Progyny Select ramp are framed as medium-term contributors, so near-term results may still be sensitive to member engagement and renewal timing (about one-third of the client book up for renewal).
Background
Progyny is a fertility benefits manager with revenue split between fertility and pharmacy benefit services; the call covers Q2 results and 2026 outlook.
Ticker impact
Progyny reported Q2 revenue of $350.5M (+5.3% reported) and guided Q3 revenue to $335M-$345M with a more pronounced summer seasonal impact.
Bias modestly positive, but expect volatility around the Q3 seasonal softness and any market reaction to guidance range and margin commentary.
The article discloses multiple decision-grade datapoints: Q2 results, Q3 revenue guidance range, full-year revenue and adjusted EBITDA guidance, and a stated driver (seasonality) for sequential revenue change. It also includes client growth, retention framing, and buyback activity that can support sentiment.
Market effects
Reinforces demand resilience in fertility benefits and highlights employer cost-containment as a driver of switching and retention dynamics.
No explicit regional effects mentioned.
Primarily US employer-sponsored fertility benefits; no global catalyst described.
Counterpoint
The Q3 guide explicitly assumes more pronounced summer seasonal softness, which could signal weaker near-term utilization despite record Q2.
Key entities
- companyProgyny
Reported Q2 2026 results and provided Q3 and full-year 2026 guidance, including seasonal assumptions and margin outlook.
- executivePeter Anevski
CEO who attributed sales momentum to employer focus on a prevalent medical need and discussed 2027 launch commitments and brownfield opportunities.
- executiveMark S. Livingston
CFO who discussed guidance drivers, including more pronounced summer seasonality for Q3 member activity.
